Skip to main content
Oxford University Press - PMC COVID-19 Collection logoLink to Oxford University Press - PMC COVID-19 Collection
letter
. 2021 Jan 6:znaa124. doi: 10.1093/bjs/znaa124

Impact of COVID-19 on colorectal cancer presentation

S Aguiar Jr 1,, R Pimenta Riechelmann 2, C Abdon Lopes de Mello 3, J C Frazão da Silva 4, I D Carrilho Diogenes 5, M Silva Andrade 6, T M Duarte de Miranda Marques 7, P R Stevanato 8, T Santoro Bezerra 9, M L Gobo Silva 10, A Lopes 11, M P Curado 12
PMCID: PMC7929226  PMID: 33711133

Abstract

This was a cross-sectional and retrospective study of the short-term effects of the COVID-19 pandemic among patients with colorectal or anal cancer treated at AA Camargo Cancer Centre, a large and comprehensive cancer centre located in Sao Paulo, the epicentre of the pandemic in Brazil. The aim was to quantify the barriers to access to treatment and diagnosis of these tumours during the pandemic in comparison with the previous year. The results showed a significant decrease in newly diagnosed patients with colorectal or anal cancer, a significant increase in patients with locally advanced disease at presentation, and an increase in the proportion of patients without insurance for coverage of costs.


Dear Editor

It is 8 months since the WHO declared the coronavirus disease (COVID-19) pandemic. The pandemic is not over, but it is believed that it will influence oncological outcomes as a consequence of delayed presentation, and difficulty in providing diagnostic investigation and treatment when hospitals are overburdened with caring for patients with COVID-191. Accurate data on the survival impact will not be available for many years, but measuring the effect of the pandemic on services now may help predict likely outcomes2–4.

This observational cross-sectional comparative analysis compared new cases of colorectal and anal cancer in the outpatient clinics of the Colorectal Surgery Service of AC Camargo Cancer Centre, Sao Paulo, Brazil, during the interval 1 March to 31 July 2020 and the same period in 2019.

There was a significant decrease in newly diagnosed patients referred, a significant increase in locally advanced disease at presentation, and increase in the proportion of patients without insurance for coverage of costs (Table 1). In 2019, 108 patients with newly diagnosed colorectal cancer were admitted, compared with 58 in the same period in 2020, comprising a decrease of 46.3 per cent. As the hospital has not stopped new appointments for patients with confirmed cancer5, the decrease may be explained by the difficulty in performing colonoscopy and by the patients’ fear of undergoing in-hospital investigation while the pandemic is ongoing. Another reason for the decrease in new cancer diagnoses is the collapse of health systems, especially those that are publicly funded. This effect can be demonstrated indirectly by the decrease in referral of patients from the public health system (Sistema Único da Saúde) to this hospital, from 21.0 per cent in 2019 to 14 per cent in 2020.

Table 1.

Clinical and socioeconomic variables in 166 patients with newly diagnosed colorectal and anal cancers, comparing March to July 2019 with March to July 2020

2019
(n = 108)
2020
(n = 58)
P *
Mean age (years) 62.9 61.8 0.591
Sex ratio (M : F) 46 : 62 30 : 28 0.163
Are of residence 0.219
  State of Sao Paulo countryside or other  state 19 (19) 14 (26)
  City of Sao Paulo metropolitan area 80 (81) 40 (74)
Reason for diagnosis 0.122
  Screening 28 (26.7) 10 (17)
  Symptomatic 77 (73.3) 48 (83)
Mean duration of symptoms (days) 123.9 135.5 0.618
Tumour location 0.159
  Colon 64 (59.3) 29 (50)
  Anorectum 44 (40.7) 29 (50)
Clinical tumour category 0.19
  cT1–T3 89 (84.8) 44 (76)
  cT4 16 (15.2) 14 (24)
Clinical node category 0.002
  cN0 73 (69.5) 26 (45)
  cN+ 32 (30.5) 32 (55)
Clinical metastasis category 0.483
  cM0 96 (91.4) 54 (93)
  cM+ 9 (8.6) 4 (7)
Clinical stage at presentation 0.002
  Not advanced (cT1–T3 N0 M0) 65 (61.3) 21 (36)
  Advanced (cT4 or cN+ or M1) 41 (38.7) 37 (64)
Type of cost coverage 0.182

  Public Health (SUS)

 

  Insurance companies

 

  Fully private

22 (21.0)

 

70 (66.7)

 

13 (12.4)

8 (14)

 

37 (64)

 

13 (22)

Insurance 0.068
  Any kind of insurance (public or private company) 92 (87.6) 45 (78)
  No insurance (fully private) 13 (12.4) 13 (22)
Continuity of treatment at ACCC 0.124
  Yes 88 (81.5) 42 (72)
  No 20 (18.5) 16 (28)

Values in parentheses are percentages. There were data missing for some variables. SUS, Sistema Único da Saúde; ACCC, AC Camargo Cancer Centre.

*

qui-squared test was used for categorical variables, except

student T test was used to compare continuous variables.

Another worrying finding is the increase in the proportion of patients without any coverage (from 12.4 to 22 per cent). This subset of patients reflects loss of insurance coverage, owing to a decrease in household income, and barriers to accessing the overcrowded but universal Brazilian public system. These patients often search for private hospitals to gain access to diagnosis and treatment, but eventually go back to the already congested public healthcare system, as they cannot afford fully private treatment. This effect can be implied from the increase in the proportion of private patients who made one or two appointments and did not continue treatment at the authors’ centre (from 18.5 to 28 per cent). These data indirectly show the migration of people from intermediate to low income levels, owing to the pandemic. As a consequence of all of these barriers, there has been a worsening of clinical stage at presentation, especially for locally advanced tumours. Late diagnosis and eventually poor cancer outcomes during the pandemic must be recognized and addressed by healthcare policy providers. We are now facing a second wave of the pandemic, and continuous efforts have to be made by private and public health systems around the world to provide timely and effective cancer care to all patients with cancer.

Disclosure. The authors declare no conflict of interest.

Contributor Information

S Aguiar, Jr, Email: samuel.aguiar@accamargo.org.br, Colorectal Cancer Service, Surgical Oncology, AC Camargo Cancer Centre, Sao Paulo, Brazil.

R Pimenta Riechelmann, Colorectal Cancer Service, Clinical Oncology, AC Camargo Cancer Centre, Sao Paulo, Brazil.

C Abdon Lopes de Mello, Colorectal Cancer Service, Clinical Oncology, AC Camargo Cancer Centre, Sao Paulo, Brazil.

J C Frazão da Silva, Resident in Surgical Oncology, AC Camargo Cancer Centre, Sao Paulo, Brazil.

I D Carrilho Diogenes, Resident in Surgical Oncology, AC Camargo Cancer Centre, Sao Paulo, Brazil.

M Silva Andrade, Resident in Surgical Oncology, AC Camargo Cancer Centre, Sao Paulo, Brazil.

T M Duarte de Miranda Marques, Colorectal Cancer Service, Surgical Oncology, AC Camargo Cancer Centre, Sao Paulo, Brazil.

P R Stevanato, Colorectal Cancer Service, Surgical Oncology, AC Camargo Cancer Centre, Sao Paulo, Brazil.

T Santoro Bezerra, Colorectal Cancer Service, Surgical Oncology, AC Camargo Cancer Centre, Sao Paulo, Brazil.

M L Gobo Silva, Colorectal Cancer Service, Radiation Oncology, AC Camargo Cancer Centre, Sao Paulo, Brazil.

A Lopes, Colorectal Cancer Service, Surgical Oncology, AC Camargo Cancer Centre, Sao Paulo, Brazil.

M P Curado, Epidemiology and Statistics, AC Camargo Cancer Centre, Sao Paulo, Brazil.

References

  • 1.CRC COVID Research Collaborative. Colorectal cancer services during the COVID-19 pandemic. Br J Surg  2020;107:e255–e256 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Sharpless NE.  COVID-19 and cancer. Science  2020;368:1290. [DOI] [PubMed] [Google Scholar]
  • 3. Sud A, Torr B, Jones ME, Broggio J, Scott S, Loveday C  et al.  Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. Lancet Oncol  2020;21:1035–1044 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Lai AG, Pasea L, Banerjee A, Denaxas S, Katsoulis M, Chang WH  et al.  Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency. medRxiv  2020; 10.1101/2020.05.27.20083287 (accessed 29 October 2020) [DOI] [Google Scholar]
  • 5. Aguiar S Junior, Baiocchi G, Duprat JP, Coimbra FJF, Makdissi FB, Vartanian JG  et al.  Value of preoperative testing for SARS-CoV-2 for elective surgeries in a cancer center during the peak of pandemic in Brazil. J Surg Oncol  2020; DOI: 10.1002/jso.26146 [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The British Journal of Surgery are provided here courtesy of Oxford University Press

RESOURCES